ATE480552T1 - Stq-peptide - Google Patents

Stq-peptide

Info

Publication number
ATE480552T1
ATE480552T1 AT04758409T AT04758409T ATE480552T1 AT E480552 T1 ATE480552 T1 AT E480552T1 AT 04758409 T AT04758409 T AT 04758409T AT 04758409 T AT04758409 T AT 04758409T AT E480552 T1 ATE480552 T1 AT E480552T1
Authority
AT
Austria
Prior art keywords
methods
antagonists
vivo
stq
peptides
Prior art date
Application number
AT04758409T
Other languages
English (en)
Inventor
Peter Brooks
Abebe Akalu
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE480552T1 publication Critical patent/ATE480552T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04758409T 2003-03-28 2004-03-26 Stq-peptide ATE480552T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45852303P 2003-03-28 2003-03-28
PCT/US2004/009332 WO2004087734A2 (en) 2003-03-28 2004-03-26 Stq-peptides

Publications (1)

Publication Number Publication Date
ATE480552T1 true ATE480552T1 (de) 2010-09-15

Family

ID=33131807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04758409T ATE480552T1 (de) 2003-03-28 2004-03-26 Stq-peptide

Country Status (8)

Country Link
US (2) US7387998B2 (de)
EP (1) EP1611151B1 (de)
JP (1) JP2006524241A (de)
AT (1) ATE480552T1 (de)
AU (1) AU2004225986B2 (de)
CA (1) CA2520372C (de)
DE (1) DE602004029016D1 (de)
WO (1) WO2004087734A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7601694B2 (en) 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
CA2554537A1 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US20060240002A1 (en) * 2005-03-11 2006-10-26 Brooks Peter C Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US20060216237A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Inhibition of angiogenesis and tumor development by IGFBP-4
US20060216236A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
US8664369B2 (en) 2007-11-01 2014-03-04 Merck Serono S.A. LH liquid formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US6071520A (en) * 1990-09-12 2000-06-06 Leadd Bv Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
AU776137B2 (en) 1999-01-06 2004-08-26 University Of Southern California Method and composition for angiogenesis inhibition
AU4187200A (en) 1999-04-01 2000-10-23 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides

Also Published As

Publication number Publication date
CA2520372A1 (en) 2004-10-14
EP1611151A4 (de) 2007-08-22
CA2520372C (en) 2013-12-24
WO2004087734A3 (en) 2005-07-28
US20040224896A1 (en) 2004-11-11
US20090226369A1 (en) 2009-09-10
AU2004225986B2 (en) 2010-11-11
EP1611151B1 (de) 2010-09-08
DE602004029016D1 (de) 2010-10-21
US7387998B2 (en) 2008-06-17
JP2006524241A (ja) 2006-10-26
EP1611151A2 (de) 2006-01-04
AU2004225986A1 (en) 2004-10-14
WO2004087734A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
DK1149111T3 (da) Fremgangsmåde og sammensætning til inhibering af angiogenese
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
MY159375A (en) Combinatorial therapy
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
EP2166845A4 (de) Alpha-connexin-c-terminale (act) peptide für die behandlung der altersbedingten makulardegeneration
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2008031016A3 (en) Heterocyclic ligands for integrin imaging and therapy
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE480552T1 (de) Stq-peptide
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2004073649A3 (en) Clk-peptide and slk-peptide
BRPI0518105A (pt) uso de antagonista da angiogênese e uso de anticorpo anti-vegf
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2009076388A3 (en) Targeting vector-phospholipid conjugates
NO20026286D0 (no) Nye peptider
GB0507598D0 (en) Composition
ATE399532T1 (de) Medizinische seife

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties